Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative

Objective The 1987 American College of Rheumatology (ACR; formerly the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticised for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA. Methods A joint working group from the ACR and the European League Against Rheumatism developed, in three phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease—this being the appropriate current paradigm underlying the disease construct ‘RA’. Results In the new criteria set, classification as ‘definite RA’ is based on the confirmed presence of synovitis in at least one joint, absence of an alternative diagnosis better explaining the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in four domains: number and site of involved joints (range 0–5), serological abnormality (range 0–3), elevated acute-phase response (range 0–1) and symptom duration (two levels; range 0–1). Conclusion This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimise the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct ‘RA’.

[1]  W. Grassi,et al.  Tips and tricks to recognize microcrystalline arthritis. , 2012, Rheumatology.

[2]  A. Kerr,et al.  Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. , 2012, The New Zealand medical journal.

[3]  Shuai Leng,et al.  Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. , 2011, Radiology.

[4]  Hyon K. Choi,et al.  Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. , 2011, Arthritis and rheumatism.

[5]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[6]  A. Silman,et al.  The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. , 2010, Arthritis and rheumatism.

[7]  A. Silman,et al.  The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I , 2010, Annals of the rheumatic diseases.

[8]  I. Peláez-Ballestas,et al.  Diagnosis of Chronic Gout: Evaluating the American College of Rheumatology Proposal, European League Against Rheumatism Recommendations, and Clinical Judgment , 2010, The Journal of Rheumatology.

[9]  C. van Weel,et al.  A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. , 2010, Archives of internal medicine.

[10]  K. Liao,et al.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[11]  D. M. van der Heijde,et al.  The prognostic value of baseline erosions in undifferentiated arthritis , 2009, Arthritis research & therapy.

[12]  H. Schumacher,et al.  Clinical Diagnostic Criteria for Gout: Comparsion With the Gold Standard of Synovial Fluid Crystal Analysis , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[13]  D. M. van der Heijde,et al.  Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature , 2008, Annals of the rheumatic diseases.

[14]  Andrew Filer,et al.  Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. , 2008, Arthritis and rheumatism.

[15]  P. Hansen,et al.  A new method for scoring additive multi‐attribute value models using pairwise rankings of alternatives , 2008 .

[16]  L. Annemans,et al.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005 , 2007, Annals of the rheumatic diseases.

[17]  Michael H Weisman,et al.  New therapies for treatment of rheumatoid arthritis , 2007, The Lancet.

[18]  J. Singh,et al.  Classification criteria in rheumatic diseases: a review of methodologic properties. , 2007, Arthritis and rheumatism.

[19]  M. Weinblatt,et al.  Optimal use of methotrexate: the advantages of tight control , 2007, Annals of the rheumatic diseases.

[20]  C. Allaart,et al.  Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. , 2007, Arthritis and rheumatism.

[21]  A. Silman,et al.  Reconciling subject differences in recruitment to clinical trials and clinical practice. , 2005, The Journal of rheumatology.

[22]  Wei Chen,et al.  Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. , 2005, Arthritis and rheumatism.

[23]  E. Massarotti,et al.  Rheumatoid Arthritis: An Overview of New and Emerging Therapies , 2005, Journal of clinical pharmacology.

[24]  W. Bilker,et al.  Gout epidemiology: results from the UK General Practice Research Database, 1990–1999 , 2005, Annals of the rheumatic diseases.

[25]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.

[26]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[27]  T. Pincus,et al.  Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[28]  G. Firestein Evolving concepts of rheumatoid arthritis , 2003, Nature.

[29]  A. Silman,et al.  Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. , 2003, Arthritis and rheumatism.

[30]  M. Uffmann,et al.  Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. , 2002, The Journal of rheumatology.

[31]  B. Pal,et al.  How is Gout Managed in Primary Care? A Review of Current Practice and Proposed Guidelines , 2000, Clinical Rheumatology.

[32]  F. Wolfe,et al.  Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. , 1998, Arthritis and rheumatism.

[33]  P. Jones,et al.  Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. , 1998, The Journal of rheumatology.

[34]  K. Bohndorf,et al.  Diagnostic radiography in rheumatoid arthritis: benefits and limitations. , 1996, Bailliere's clinical rheumatology.

[35]  A. van der Heide,et al.  The Effectiveness of Early Treatment with Second-Line Antirheumatic Drugs , 1996, Annals of Internal Medicine.

[36]  F. Wolfe,et al.  The natural history of rheumatoid arthritis. , 1996, The Journal of rheumatology. Supplement.

[37]  D. Heijde Joint erosions and patients with early rheumatoid arthritis , 1995 .

[38]  D. van der Heijde,et al.  Joint erosions and patients with early rheumatoid arthritis. , 1995, British journal of rheumatology.

[39]  K. Aho,et al.  Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. , 1993, The Journal of rheumatology.

[40]  H. Isomäki Long-term outcome of rheumatoid arthritis. , 1992, Scandinavian journal of rheumatology. Supplement.

[41]  T. Tuomi,et al.  Rheumatoid factors antedating clinical rheumatoid arthritis. , 1991, The Journal of rheumatology.

[42]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[43]  D. Symmons,et al.  LONG-TERM OUTCOME OF TREATING RHEUMATOID ARTHRITIS: RESULTS AFTER 20 YEARS , 1987, The Lancet.

[44]  J. Fries,et al.  Survival, prognosis, and causes of death in rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[45]  T. Pincus,et al.  Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. , 1984, Arthritis and rheumatism.

[46]  D. Mccarty,et al.  Preliminary criteria for the classification of the acute arthritis of primary gout. , 1977, Arthritis and rheumatism.

[47]  J. S. Lawrence,et al.  The Epidemiology of Chronic Rheumatism , 1964 .